Ten post jest także dostępny w języku: polski
Dimitri Gitas has been appointed Managing Director of the Polish branch of biopharmaceutical company MSD Poland as of 1 February 2021. MSD is known as Merck in the United States and Canada.
Dimitri Gitas has a degree in biochemistry from the University of Ottawa and has been involved in the pharmaceutical industry for many years. He has worked for Merck for nearly 17 years in various operational positions. It has been announced that Dimitri Gitas will head the Management Board of MSD Polska Sp. z o.o., covering the areas of Human Health, Clinical Research and Data Management Center. Immediately prior to joining the Polish branch of MSD, Gitas served for 2.5 years as Business Unit Director at MSD in Greece.
His presence in Poland is expected to drive the company’s operations on the Polish market, while focusing attention on new, promising directions of development. The company wants to strengthen its position in our country by providing patients with access to modern therapies, developing innovative research projects and digitalisation.
MSD in Poland since 30 years
Dimitri Gitas is moving to Poland at a difficult time in dealing with the effects of the coronavirus pandemic. Although he will undoubtedly face many challenges. The clinical trials industry is in a real quagmire. While the world is struggling with the economic effects of the pandemic, clinical trials on COVID-19 vaccines and drugs are conducted all over the world.
MSD has been active in Poland since 1991. The company said that its Data Management Centre, which has operated in Warsaw for the past 10 years, is one of six such centres worldwide which manage MSD’s clinical trial data and pharmacovigilance data.